-
1
-
-
84865580488
-
Low-dose IL-2 for in vivo expansion of CD4+ and CD8+ regulatory T cells in nonhuman primates
-
Aoyama, A., Klarin, D., Yamada, Y., et al. (2012). Low-dose IL-2 for in vivo expansion of CD4+ and CD8+ regulatory T cells in nonhuman primates. Am. J. Transplant. 12, 2532-2537.
-
(2012)
Am. J. Transplant.
, vol.12
, pp. 2532-2537
-
-
Aoyama, A.1
Klarin, D.2
Yamada, Y.3
-
2
-
-
84867437406
-
Im-munotherapy against HPV16/18 generates potent TH1 and cy-totoxic cellular immune responses
-
Bagarazzi, M.L., Yan, J., Morrow, M.P., et al. (2012). Im-munotherapy against HPV16/18 generates potent TH1 and cy-totoxic cellular immune responses. Sci. Transl. Med. 4, 155ra138.
-
(2012)
Sci. Transl. Med.
, vol.4
-
-
Bagarazzi, M.L.1
Yan, J.2
Morrow, M.P.3
-
3
-
-
0038128194
-
Cutting edge: Rapid in vivo killing by memory CD8 T cells
-
Barber, D.L., Wherry, E.J., and Ahmed, R. (2003). Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171, 27-31.
-
(2003)
J. Immunol.
, vol.171
, pp. 27-31
-
-
Barber, D.L.1
Wherry, E.J.2
Ahmed, R.3
-
4
-
-
50849126768
-
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia
-
Bosch, F.X., Burchell, A.N., Schiffman, M., et al. (2008). Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26 Suppl 10, K1-K16.
-
(2008)
Vaccine
, vol.26
, Issue.SUPPL. 10
-
-
Bosch, F.X.1
Burchell, A.N.2
Schiffman, M.3
-
5
-
-
0034652784
-
Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene
-
Chen, C.H., Wang, T.L., Hung, C.F., et al. (2000). Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60, 1035-1042.
-
(2000)
Cancer Res.
, vol.60
, pp. 1035-1042
-
-
Chen, C.H.1
Wang, T.L.2
Hung, C.F.3
-
6
-
-
0034788572
-
Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen
-
Cheng, W.F., Hung, C.F., Chai, C.Y., et al. (2001). Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. 108, 669-678.
-
(2001)
J. Clin. Invest.
, vol.108
, pp. 669-678
-
-
Cheng, W.F.1
Hung, C.F.2
Chai, C.Y.3
-
7
-
-
0036204348
-
Cancer im-munotherapy using sindbis virus replicon particles encoding a VP22-antigen fusion
-
Cheng, W.F., Hung, C.F., Hsu, K.F., et al. (2002). Cancer im-munotherapy using sindbis virus replicon particles encoding a VP22-antigen fusion. Hum. Gene Ther. 13, 553-568.
-
(2002)
Hum. Gene Ther.
, vol.13
, pp. 553-568
-
-
Cheng, W.F.1
Hung, C.F.2
Hsu, K.F.3
-
8
-
-
0031060327
-
Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2
-
Chow, Y.H., Huang, W.L., Chi, W.K., et al. (1997). Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 71, 169-178.
-
(1997)
J. Virol.
, vol.71
, pp. 169-178
-
-
Chow, Y.H.1
Huang, W.L.2
Chi, W.K.3
-
9
-
-
0031953116
-
Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by co-delivery of various cytokine genes
-
Chow, Y.H., Chiang, B.L., Lee, Y.L., et al. (1998). Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by co-delivery of various cytokine genes. J. Immunol. 160, 1320-1329.
-
(1998)
J. Immunol.
, vol.160
, pp. 1320-1329
-
-
Chow, Y.H.1
Chiang, B.L.2
Lee, Y.L.3
-
10
-
-
0034527326
-
Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7
-
Chu, N.R., Wu, H.B., Wu, T.C., et al. (2000). Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7. Cell Stress Chaperones 5, 401-405.
-
(2000)
Cell Stress Chaperones
, vol.5
, pp. 401-405
-
-
Chu, N.R.1
Wu, H.B.2
Wu, T.C.3
-
11
-
-
0029820526
-
DNA-based immunization by in vivo transfection of dendritic cells
-
Condon, C., Watkins, S.C., Celluzzi, C.M., et al. (1996). DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2, 1122-1128.
-
(1996)
Nat. Med.
, vol.2
, pp. 1122-1128
-
-
Condon, C.1
Watkins, S.C.2
Celluzzi, C.M.3
-
12
-
-
0037019901
-
Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine
-
de Jong, A., O'Neill, T., Khan, A.Y., et al. (2002). Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20, 3456-3464.
-
(2002)
Vaccine
, vol.20
, pp. 3456-3464
-
-
De Jong, A.1
O'Neill, T.2
Khan, A.Y.3
-
13
-
-
79958039517
-
Enhanced anti-tumor effects of a gene gun delivered DNA vaccine encoding the human papillomavirus type-16 (HPV-16) oncoproteins genetically fused to the herpes virus glycoprotein D (gD)
-
Diniz, M.O., and Ferreira, L.C. (2011). Enhanced anti-tumor effects of a gene gun delivered DNA vaccine encoding the human papillomavirus type-16 (HPV-16) oncoproteins genetically fused to the herpes virus glycoprotein D (gD). Braz. J. Biomed. Res. 44, 421-427.
-
(2011)
Braz. J. Biomed. Res.
, vol.44
, pp. 421-427
-
-
Diniz, M.O.1
Ferreira, L.C.2
-
14
-
-
77957863130
-
Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glyco-protein D
-
Diniz, M.O., Lasaro, M.O., Ertl, H.C., and Ferreira, L.C. (2010). Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glyco-protein D. Clin. Vaccine Immunol. 17, 1576-1583.
-
(2010)
Clin. Vaccine Immunol.
, vol.17
, pp. 1576-1583
-
-
Diniz, M.O.1
Lasaro, M.O.2
Ertl, H.C.3
Ferreira, L.C.4
-
15
-
-
0029201560
-
Cytokines as vaccine adjuvants: Current status and potential applications
-
Dong, P., Brunn, C., and Ho, R.J. (1995). Cytokines as vaccine adjuvants: current status and potential applications. Pharm. Biotechnol. 6, 625-643.
-
(1995)
Pharm. Biotechnol.
, vol.6
, pp. 625-643
-
-
Dong, P.1
Brunn, C.2
Ho, R.J.3
-
16
-
-
34548128005
-
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III
-
Einstein, M.H., Kadish, A.S., Burk, R.D., et al. (2007). Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III Gynecol. Oncol. 106, 453-460.
-
(2007)
Gynecol. Oncol.
, vol.106
, pp. 453-460
-
-
Einstein, M.H.1
Kadish, A.S.2
Burk, R.D.3
-
17
-
-
0019429671
-
Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2
-
Farrar, W.L., Johnson, H.M., and Farrar, J.J. (1981). Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. J. Immunol. 126, 1120-1125.
-
(1981)
J. Immunol.
, vol.126
, pp. 1120-1125
-
-
Farrar, W.L.1
Johnson, H.M.2
Farrar, J.J.3
-
18
-
-
0027320440
-
Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillo-mavirus type 16-transformed cells
-
Feltkamp, M.C., Smits, H.L., Vierboom, M.P., et al. (1993). Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillo-mavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242-2249.
-
(1993)
Eur. J. Immunol.
, vol.23
, pp. 2242-2249
-
-
Feltkamp, M.C.1
Smits, H.L.2
Vierboom, M.P.3
-
19
-
-
1442305202
-
ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: A randomized controlled trial
-
Garcia, F., Petry, K.U., Muderspach, L., et al. (2004). ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 103, 317-326.
-
(2004)
Obstet. Gynecol.
, vol.103
, pp. 317-326
-
-
Garcia, F.1
Petry, K.U.2
Muderspach, L.3
-
20
-
-
0031066827
-
Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids
-
Geissler, M., Gesien, A., Tokushige, K., and Wands, J.R. (1997). Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J. Immunol. 158, 1231-1237.
-
(1997)
J. Immunol.
, vol.158
, pp. 1231-1237
-
-
Geissler, M.1
Gesien, A.2
Tokushige, K.3
Wands, J.R.4
-
21
-
-
0036114412
-
Activity of HspE7, a novel immunotherapy, in patients with anogenital warts
-
Goldstone, S.E., Palefsky, J.M., Winnett, M.T., and Neefe, J.R. (2002). Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis. Colon Rectum 45, 502-507.
-
(2002)
Dis. Colon Rectum
, vol.45
, pp. 502-507
-
-
Goldstone, S.E.1
Palefsky, J.M.2
Winnett, M.T.3
Neefe, J.R.4
-
22
-
-
0029177445
-
Cytokines as immunological adjuvants
-
Heath, A.W. (1995). Cytokines as immunological adjuvants. Pharm. Biotechnol. 6, 645-658.
-
(1995)
Pharm. Biotechnol.
, vol.6
, pp. 645-658
-
-
Heath, A.W.1
-
23
-
-
41149160918
-
Antigen-specific immunotherapy of cervical and ovarian cancer
-
Hung, C.F., Wu, T.C., Monie, A., and Roden, R. (2008). Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol. Rev. 222, 43-69.
-
(2008)
Immunol. Rev.
, vol.222
, pp. 43-69
-
-
Hung, C.F.1
Wu, T.C.2
Monie, A.3
Roden, R.4
-
24
-
-
0036786797
-
Effect of herpes simplex virus-1 gD or gD-IL-2 DNA vaccine on herpetic ker-atitis
-
Inoue, T., Inoue, Y., Hayashi, K., et al. (2002). Effect of herpes simplex virus-1 gD or gD-IL-2 DNA vaccine on herpetic ker-atitis. Cornea 21, S79-S85.
-
(2002)
Cornea
, vol.21
-
-
Inoue, T.1
Inoue, Y.2
Hayashi, K.3
-
25
-
-
0031569963
-
Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines
-
Iwasaki, A., Stiernholm, B.J., Chan, A.K., et al. (1997). Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. 158, 4591-4601.
-
(1997)
J. Immunol.
, vol.158
, pp. 4591-4601
-
-
Iwasaki, A.1
Stiernholm, B.J.2
Chan, A.K.3
-
26
-
-
84859575285
-
Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced antitumor effects
-
Kang, T.H., Mao, C.P., He, L., et al. (2012). Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced antitumor effects. PLoS One 7, e35141.
-
(2012)
PLoS One
, vol.7
-
-
Kang, T.H.1
Mao, C.P.2
He, L.3
-
27
-
-
58549113969
-
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity
-
Karanam, B., Gambhira, R., Peng, S., et al. (2009). Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 27, 1040-1049.
-
(2009)
Vaccine
, vol.27
, pp. 1040-1049
-
-
Karanam, B.1
Gambhira, R.2
Peng, S.3
-
28
-
-
40549129230
-
Phase i immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity
-
Kenter, G.G., Welters, M.J., Valentijn, A.R., et al. (2008). Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14, 169-177.
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 169-177
-
-
Kenter, G.G.1
Welters, M.J.2
Valentijn, A.R.3
-
29
-
-
0034802089
-
Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8 T-cell responses that home to the tumor site
-
Lamikanra, A., Pan, Z.K., Isaacs, S.N., et al. (2001). Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8 T-cell responses that home to the tumor site. J. Virol. 75, 9654-9664.
-
(2001)
J. Virol.
, vol.75
, pp. 9654-9664
-
-
Lamikanra, A.1
Pan, Z.K.2
Isaacs, S.N.3
-
30
-
-
63349088416
-
Potentiating vaccine im-munogenicity by manipulating the HVEM/BTLA pathway and other co-stimulatory and co-inhibitory signals of the immune system
-
Lasaro, M.O., and Ertl, H.C. (2009). Potentiating vaccine im-munogenicity by manipulating the HVEM/BTLA pathway and other co-stimulatory and co-inhibitory signals of the immune system. Hum. Vaccin. 5, 6-14.
-
(2009)
Hum. Vaccin.
, vol.5
, pp. 6-14
-
-
Lasaro, M.O.1
Ertl, H.C.2
-
31
-
-
28944442195
-
Antitumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from human herpes virus-1
-
Lasaro, M.O., Diniz, M.O., Reyes-Sandoval, A., et al. (2005). Antitumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from human herpes virus-1. Microb. Infection 7, 1541-1550.
-
(2005)
Microb. Infection
, vol.7
, pp. 1541-1550
-
-
Lasaro, M.O.1
Diniz, M.O.2
Reyes-Sandoval, A.3
-
32
-
-
38949214015
-
Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses
-
Lasaro, M.O., Tatsis, N., Hensley, S.E., et al. (2008). Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat. Med. 14, 205-212.
-
(2008)
Nat. Med.
, vol.14
, pp. 205-212
-
-
Lasaro, M.O.1
Tatsis, N.2
Hensley, S.E.3
-
33
-
-
62549120308
-
HPV vaccination: The beginning of the end of cervical cancer? A review
-
Lepique, A.P., Rabachini, T., and Villa, L.L. (2009). HPV vaccination: the beginning of the end of cervical cancer? A review. Mem. Inst. Oswaldo Cruz. 104, 1-10.
-
(2009)
Mem. Inst. Oswaldo Cruz.
, vol.104
, pp. 1-10
-
-
Lepique, A.P.1
Rabachini, T.2
Villa, L.L.3
-
34
-
-
44749088862
-
Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting
-
Li, W., Li, S., Hu, Y., et al. (2008). Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting. Vaccine 26, 3282-3290.
-
(2008)
Vaccine
, vol.26
, pp. 3282-3290
-
-
Li, W.1
Li, S.2
Hu, Y.3
-
35
-
-
0030068375
-
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
-
Lin, K.Y., Guarnieri, F.G., Staveley-O'Carroll, K.F., et al. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21-26.
-
(1996)
Cancer Res.
, vol.56
, pp. 21-26
-
-
Lin, K.Y.1
Guarnieri, F.G.2
Staveley-O'Carroll, K.F.3
-
36
-
-
36549019001
-
DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity
-
Lin, C.T., Tsai, Y.C., He, L., et al. (2007). DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol. Lett. 114, 86-93.
-
(2007)
Immunol. Lett.
, vol.114
, pp. 86-93
-
-
Lin, C.T.1
Tsai, Y.C.2
He, L.3
-
37
-
-
0033994625
-
Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer
-
Liu, D.W., Tsao, Y.P., Kung, J.T., et al. (2000). Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol. 74, 2888-2894.
-
(2000)
J. Virol.
, vol.74
, pp. 2888-2894
-
-
Liu, D.W.1
Tsao, Y.P.2
Kung, J.T.3
-
38
-
-
77952940985
-
HPV and therapeutic vaccines: Where are we in 2010?
-
Ma, B., Xu, Y., Hung, C.F., and Wu, T.C. (2010). HPV and therapeutic vaccines: where are we in 2010? Curr. Cancer Ther. Rev. 6, 81-103.
-
(2010)
Curr. Cancer Ther. Rev.
, vol.6
, pp. 81-103
-
-
Ma, B.1
Xu, Y.2
Hung, C.F.3
Wu, T.C.4
-
39
-
-
33747881589
-
Chapter 1: HPV in the etiology of human cancer
-
Muñoz, N., Castellsagué, X., de González, A.B., and Gissmann, L. (2006). Chapter 1: HPV in the etiology of human cancer. Vaccine 24 Suppl 3, S3/1-10.
-
(2006)
Vaccine
, vol.24
, Issue.SUPPL. 3
-
-
Muñoz, N.1
Castellsagué, X.2
De González, A.B.3
Gissmann, L.4
-
40
-
-
14944385553
-
Global cancer statistics
-
Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2002). Global cancer statistics. CA Cancer J. Clin. 55, 74-108.
-
(2002)
CA Cancer J. Clin.
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
41
-
-
82955240694
-
Purified herpes simplex type 1 glycoprotein D (gD) genetically fused with the type 16 human papillomavirus E7 oncoprotein enhances antigen-specific CD8+ T-cell responses and confers protective antitumor immunity
-
Porchia, B.F., Diniz, M.O., Cariri, F.A., et al. (2011). Purified herpes simplex type 1 glycoprotein D (gD) genetically fused with the type 16 human papillomavirus E7 oncoprotein enhances antigen-specific CD8+ T-cell responses and confers protective antitumor immunity. Mol. Pharm. 8, 2320-2330.
-
(2011)
Mol. Pharm.
, vol.8
, pp. 2320-2330
-
-
Porchia, B.F.1
Diniz, M.O.2
Cariri, F.A.3
-
42
-
-
0024426529
-
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients
-
Rosenberg, S.A., Lotze, M.T., Yang, J.C., et al. (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474-485.
-
(1989)
Ann. Surg.
, vol.210
, pp. 474-485
-
-
Rosenberg, S.A.1
Lotze, M.T.2
Yang, J.C.3
-
43
-
-
54049119238
-
Involvement of HVEM receptor in activation of nuclear factor kappaB by herpes simplex virus 1 glycoprotein D
-
Sciortino, M.T., Medici, M.A., Marino-Merlo, F., et al. (2008). Involvement of HVEM receptor in activation of nuclear factor kappaB by herpes simplex virus 1 glycoprotein D. Cell Mi-crobiol. 10, 2297-2311.
-
(2008)
Cell Mi-crobiol.
, vol.10
, pp. 2297-2311
-
-
Sciortino, M.T.1
Medici, M.A.2
Marino-Merlo, F.3
-
44
-
-
0038405322
-
Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA
-
Sheets, E.E., Urban, R.G., Crum, C.P., et al. (2003). Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am. J. Obstet. Gynecol. 188, 916-926.
-
(2003)
Am. J. Obstet. Gynecol.
, vol.188
, pp. 916-926
-
-
Sheets, E.E.1
Urban, R.G.2
Crum, C.P.3
-
45
-
-
0034103589
-
Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer
-
Song, K., Chang, Y., and Prud'homme, G.J. (2000). Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Gene Ther. 7, 481-492.
-
(2000)
Gene Ther.
, vol.7
, pp. 481-492
-
-
Song, K.1
Chang, Y.2
Prud'Homme, G.J.3
-
46
-
-
80054850189
-
The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation
-
Steinberg, M.W., Cheung, T.C., and Ware, C.F. (2011). The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol. Rev. 244, 169-187.
-
(2011)
Immunol. Rev.
, vol.244
, pp. 169-187
-
-
Steinberg, M.W.1
Cheung, T.C.2
Ware, C.F.3
-
47
-
-
84860991516
-
-
Tian, D.Y., Sun, Y., Wai, S.F., et al. (2012). Enhancement of the immunogenicity of an alphavirus replicon-based DNA vaccine against classical swine fever by electroporation and co-injection with a plasmid expressing porcine interleukin 2. 30, 3587-3594.
-
(2012)
Enhancement of the Immunogenicity of An Alphavirus Replicon-based DNA Vaccine Against Classical Swine Fever by Electroporation and Co-injection with A Plasmid Expressing Porcine Interleukin 2.
, vol.30
, pp. 3587-3594
-
-
Tian, D.Y.1
Sun, Y.2
Wai, S.F.3
-
48
-
-
34447272278
-
The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection
-
Toubaji, A., Hill, S., Terabe, M., et al. (2007). The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 25, 5882-5891.
-
(2007)
Vaccine
, vol.25
, pp. 5882-5891
-
-
Toubaji, A.1
Hill, S.2
Terabe, M.3
-
49
-
-
73949130821
-
Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia
-
Van Doorslaer, K., Reimers, L.L., Studentsov, Y.Y., et al. (2009). Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. Gynecol. Oncol. 116, 208-212.
-
(2009)
Gynecol. Oncol.
, vol.116
, pp. 208-212
-
-
Van Doorslaer, K.1
Reimers, L.L.2
Studentsov, Y.Y.3
-
50
-
-
84866551579
-
Vaccine-induced effector-memory CD8+ T-cell responses predict therapeutic efficacy against tumors
-
van Duikeren, S., Fransen, M.F., Redeker, A., et al. (2012). Vaccine-induced effector-memory CD8+ T-cell responses predict therapeutic efficacy against tumors. J. Immunol. 189, 3397-3403.
-
(2012)
J. Immunol.
, vol.189
, pp. 3397-3403
-
-
Van Duikeren, S.1
Fransen, M.F.2
Redeker, A.3
-
51
-
-
33746547247
-
The biology of interleukin-2 and inter-leukin-15: Implications for cancer therapy and vaccine design
-
Waldmann, T.A. (2006). The biology of interleukin-2 and inter-leukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595-601.
-
(2006)
Nat. Rev. Immunol.
, vol.6
, pp. 595-601
-
-
Waldmann, T.A.1
-
52
-
-
0032167401
-
A plasmid encoding murine granulocyte-macrophage colonystimulating factor increases protection conferred by a malaria DNA vaccine
-
Weiss, W.R., Ishii, K.J., Hedstrom, R.C., et al. (1998). A plasmid encoding murine granulocyte-macrophage colonystimulating factor increases protection conferred by a malaria DNA vaccine. J. Immunol. 161, 2325-2332.
-
(1998)
J. Immunol.
, vol.161
, pp. 2325-2332
-
-
Weiss, W.R.1
Ishii, K.J.2
Hedstrom, R.C.3
-
53
-
-
40549110815
-
Induction of tumorspecific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine
-
Welters, M.J., Kenter, G.G., Piersma, S.J., et al. (2008). Induction of tumorspecific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14, 178-187.
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 178-187
-
-
Welters, M.J.1
Kenter, G.G.2
Piersma, S.J.3
-
54
-
-
33845888804
-
Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene
-
Zhang, X., Divangahi, M., Ngai, P., et al. (2007). Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine 25, 1342-1352.
-
(2007)
Vaccine
, vol.25
, pp. 1342-1352
-
-
Zhang, X.1
Divangahi, M.2
Ngai, P.3
-
55
-
-
70350359428
-
Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8+ T-cell responses and anti-tumor effects
-
Zong, J., Peng, Q., Wang, Q., et al. (2009). Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8+ T-cell responses and anti-tumor effects. Oncol. Rep. 22, 953-961.
-
(2009)
Oncol. Rep.
, vol.22
, pp. 953-961
-
-
Zong, J.1
Peng, Q.2
Wang, Q.3
-
56
-
-
0030577120
-
Papillomavirus infections-A major cause of human cancers
-
zur Hausen, H. ( 1996). Papillomavirus infections-a major cause of human cancers. Biochim. Biophys. Acta 1288, 55-78.
-
(1996)
Biochim. Biophys. Acta
, vol.1288
, pp. 55-78
-
-
Zur Hausen, H.1
-
57
-
-
0036559896
-
Papillomaviruses and cancer: From basic studies to clinical application
-
zur Hausen, H. ( 2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2, 342-350.
-
(2002)
Nat. Rev. Cancer
, vol.2
, pp. 342-350
-
-
Zur Hausen, H.1
-
58
-
-
0036644556
-
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides
-
Zwaveling, S., Ferreira Mota, S.C., Nouta, J., et al. (2002). Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358.
-
(2002)
J. Immunol.
, vol.169
, pp. 350-358
-
-
Zwaveling, S.1
Ferreira Mota, S.C.2
Nouta, J.3
|